Francesco Ciscato
University of Padua
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Francesco Ciscato.
ChemistryOpen | 2015
Chiara Nardon; Federica Chiara; Leonardo Brustolin; Alberto Gambalunga; Francesco Ciscato; Andrea Rasola; Andrea Trevisan; Dolores Fregona
Transition metals offer many possibilities in developing potent chemotherapeutic agents. They are endowed with a variety of oxidation states, allowing for the selection of their coordination numbers and geometries via the choice of proper ligands, leading to the tuning of their final biological properties. We report here on the synthesis, physico-chemical characterization, and solution behavior of two gold(III) pyrrolidinedithiocarbamates (PDT), namely [AuIIIBr2(PDT)] and [AuIIICl2(PDT)]. We found that the bromide derivative was more effective than the chloride one in inducing cell death for several cancer cell lines. [AuIIIBr2(PDT)] elicited oxidative stress with effects on the permeability transition pore, a mitochondrial channel whose opening leads to cell death. More efficient antineoplastic strategies are required for the widespread burden that is cancer. In line with this, our results indicate that [AuIIIBr2(PDT)] is a promising antineoplastic agent that targets cellular components with crucial functions for the survival of tumor cells.
Life Sciences | 2018
S. Fasolato; Elisabetta Trevellin; Mariagrazia Ruvoletto; Marnie Granzotto; Giacomo Zanus; Elisa Boscaro; Enrico Babetto; Liliana Terrin; Maria Alberta Battocchio; Francesco Ciscato; C. Turato; S. Quarta; Umberto Cillo; Patrizia Pontisso; Roberto Vettor
Aims: In hepatocellular carcinoma (HCC), the regulatory protease Dipeptidyl‐peptidase IV (DPPIV/CD26), that possesses pro‐apoptotic properties, has been found abnormally regulated. The protease inhibitor SerpinB3, exerting anti‐apoptotic activity, has also been described to be upregulated, especially in HCCs with poor prognosis. The aim of this study was to investigate the possible relationship between these two molecules in HCC patients and in experimental models. Materials and methods: DPPIV/CD26 and SerpinB3 expression was measured in liver specimens of 67 patients with HCC. HepG2 and Huh7 cells, stably transfected to overexpress SerpinB3, and respective control cells were used to assess biological and metabolic modifications of DPPIV/CD26 activity induced by this serpin. Key findings: DPPIV/CD26 and SerpinB3 were localized in the same tumoral areas and both molecules were correlated with the grade of tumor differentiation, with the highest values detected in GI tumors. Cell lines over‐expressing SerpinB3 displayed upregulation of DPPIV/CD26, likely as a feedback mechanism, due to the DPPIV/CD26 protease activity inhibition by SerpinB3, as confirmed by the similar behavior induced by the inhibitor Sitagliptin. Moreover, they exhibited lower glycogen storage and higher lipid accumulation, typical effects of DPPIV/CD26. Significance: A close connection between SerpinB3 and DPPPIV has been identified, but further studies are required to better understand the mechanism by which these proteins communicate and exert metabolic effects in HCC.
Frontiers in Oncology | 2018
Giuseppe Cannino; Francesco Ciscato; Ionica Masgras; Carlos Sànchez-Martìn; Andrea Rasola
Mitochondria are dynamic organelles that exchange a multiplicity of signals with other cell compartments, in order to finely adjust key biological routines to the fluctuating metabolic needs of the cell. During neoplastic transformation, cells must provide an adequate supply of the anabolic building blocks required to meet a relentless proliferation pressure. This can occur in conditions of inconstant blood perfusion leading to variations in oxygen and nutrient levels. Mitochondria afford the bioenergetic plasticity that allows tumor cells to adapt and thrive in this ever changing and often unfavorable environment. Here we analyse how mitochondria orchestrate the profound metabolic rewiring required for neoplastic growth.
Oncotarget | 2014
Francesco Ciscato; Marco Sciacovelli; G. Villano; C. Turato; Paolo Bernardi; Andrea Rasola; Patrizia Pontisso
Cell Reports | 2017
Ionica Masgras; Francesco Ciscato; Anna Maria Brunati; Elena Tibaldi; Stefano Indraccolo; Matteo Curtarello; Federica Chiara; Giuseppe Cannino; Elena Papaleo; Matteo Lambrughi; Giulia Guzzo; Alberto Gambalunga; Marco Pizzi; Vincenza Guzzardo; Massimo Rugge; Stefania Edith Vuljan; Fiorella Calabrese; Paolo Bernardi; Andrea Rasola
BMC Cell Biology | 2014
G. Villano; C. Turato; S. Quarta; Mariagrazia Ruvoletto; Francesco Ciscato; Liliana Terrin; R. Semeraro; Claudia Paternostro; Maurizio Parola; Domenico Alvaro; Paolo Bernardi; Angelo Gatta; Patrizia Pontisso
Digestive and Liver Disease | 2016
M. Ruvoletto; S. Fasolato; E. Trevellin; M. Granzotto; Giacomo Zanus; E. Babetto; Liliana Terrin; M. Battocchio; Francesco Ciscato; C. Turato; Umberto Cillo; Patrizia Pontisso; Roberto Vettor
Biochimica et Biophysica Acta | 2016
Ionica Masgras; Francesco Ciscato; Giuseppe Cannino; Carlos Sanchez Martin; Marco Pizzi; Claudio Laquatra; Andrea Rasola
Digestive and Liver Disease | 2013
Francesco Ciscato; M. Sciacovelli; M. Ruvoletto; C. Turato; S. Quarta; G. Villano; Angelo Gatta; P. Bernardi; A. Rasola; Patrizia Pontisso
Biochimica et Biophysica Acta | 2012
Francesco Ciscato; Marco Sciacovelli; Mariagrazia Ruvoletto; Paolo Bernardi; Andrea Rasola; Patrizia Pontisso